MedPath

Optimal timing of antimicrobial prophylaxis prior to colorectal cancer surgeryA retrospective analysis among 531 patients

Conditions
C18
C20
Malignant neoplasm of colon
Malignant neoplasm of rectum
Registration Number
DRKS00030355
Lead Sponsor
niversitätsklinikum Brandenburg an der Havel
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
531
Inclusion Criteria

Electronic files of people who had surgery for colorectal cancer and received cefuroxime/metronidazole, piperacillin/tazobactam, or mezlocillin/sulbactam were analyzed

Exclusion Criteria

Patients, who received neither cefuroxime/metronidazole nor piperacillin/tazobactam or mezlocillin/sulbactam were excluded.

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rate SSI postoperatively within 30 days
Secondary Outcome Measures
NameTimeMethod
Rate SSO, SSOPI postoperatively within 30 days
© Copyright 2025. All Rights Reserved by MedPath